Navigation Links
Pharmasset Reports Fiscal First Quarter 2009 Financial Results
Date:2/9/2009

smith@pharmasset.com>richard.smith@pharmasset.com Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation,, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended December 31, 2008 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission. 

                            PHARMASSET, INC.
      CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE NET LOSS
                               (UNAUDITED)

                                               Three Months Ended
                                                  December 31,
                                                  ------------
                                               2008          2007
             
'/>"/>
SOURCE  Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 

Related biology technology :

1. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
5. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
10. Pharmasset Joins Russell 3000 Index
11. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...RNewswire-FirstCall/ - Microbix Biosystems Inc. (t... the Form 52-109F1 Certification of Annual Filings...d James Long, the Chief Financial Officer (the "Of...onnection with the annual audited financial statem...The Company initially filed the annual financial s...
(Date:11/6/2009)... Nov. 6 ,, 3Q09 Co... Qutenza(TM) E.U. Marketing Authorization to Astel... in commercial readiness activities Expanded mana...Marketing; and Director, Commercial Operations Ap...nd Audit Committee chairman , Upcoming 2009...
(Date:11/5/2009)...one hybrid . . . , Fuel economy ratings for th...t the www.fueleconomy.gov web site, which Oak Ri...r the U.S. Department of Energy and the U.S. Envir...icles on the best fuel economy list are hybrid ele...ighway). "This list proves that hybrids have gone ...
(Date:11/5/2009)...lif., Nov. 5 ThermoGenes...nnovative products for processing and storing adul... quarter of fiscal 2010. ,, For the quarter end...es of $5.2 million, a 15 percent increase over rev...ago. The Company said the key contributors to the ...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8
.... April 20 Advanced Instruments, Inc . today i...mometer as the first true automation-friendly osmo...e Advanced(R) 2020-BIO Multi-Sample Osmometer ...efines -- automation capabilities for osmolality t...Kelly Peterson, Product Manager, Advanced Instrume...
...N, April 20 Santaris Pharma announced today,promi... of microRNA-targeted,therapeutics against cancer ...ucleic Acid (LNA) Drug Platform. In both in vitro ...ed LNA-antimiR(R),s demonstrated outstanding,recog...NAs due to their high,specificity and affinity. Th...
...ril 20 Psylin Neurosciences Inc., a joint ventu...ceuticals, Inc. and PsychoGenics, Inc. announced t...t of a novel compound, PSN0041, for the treatment ...com/cgi-bin/prnh/20090420/LA01157LOGO ) , , PS...tide hormone library, PHORMOL, was identified as h...
Other Biology Technology:Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry 2Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry 3LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs 2Psylin Neurosciences Commences Development of Compound for Depression 2Psylin Neurosciences Commences Development of Compound for Depression 3
(Date:11/6/2009)...sary this month of the publication of On the Origi... Sciences (AIBS) is publishing open access two pee...istoric insights into evolution. , The two articl...rnia, Berkeley, and James T. Costa of Western Caro...t Charles Darwin," appeared in the October issue o...
(Date:11/6/2009)...9) The Monell Center and the Chinese Academy of S...ional Meeting on Taste and Smell Research. Organiz...eting will be the first international meeting on t...er, Chief Executive Officer, American Association ...sher of Science magazine, will open the meeting wi...
(Date:11/5/2009)... awarded a training grant in the amount of $2,756,...ntegrative Graduation Education and Research Train... to be awarded to Kent State. The grant, which is ...t Act of 2009, runs through 2014. , The grant fu...quatic resource sensing (EARS). The purpose of the...
Breaking Biology News(10 mins):Monell Center joins with CAS to host Beijing meeting on taste and smell research 2Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2Mayo Clinic physician receives first PASSOR Legacy Award 60163 1New American Chemical Society podcast 3A Tiny sea creature and a new medical adhesive 10546 1Stanford researchers awarded 246 27 million to study energy efficiency and human behavior 10541 1Stanford researchers awarded 246 27 million to study energy efficiency and human behavior 10541 2
...ll needs both to build new and to degrade old or d...ntracellular systems work in concert to keep the c...eins. When proteins or peptides mutate, they can p...tracellular environment. In Huntington,s disease (...in gene eventually causes the cell to build up int...
...cientists has announced a major expansion of a lin...s in living organisms. The expansion provides ter... events that occur when a pathogenic or beneficial...events is crucial for developing new interventions...obes while preserving or encouraging the presence ...
...they won,t be able to understand the brain until t...how billions of neurons are interconnected. Now, r...udies have jumped what many believe to be a major ... the connections to a single neuron. , In the Marc...escribe how they modified the deadly rabies virus,...
Other Biology News:Proteasome activator enhances survival of Huntington's disease neuronal model cells 2Uniform language for describing genes of pathogenic and beneficial microbes 2Uniform language for describing genes of pathogenic and beneficial microbes 3Deconstructing brain wiring, one neuron at a time 2Deconstructing brain wiring, one neuron at a time 3
Plastic Glove Boxes from Terra Universal, Inc.
...w Hummingbird has the ability to quickly and accur...kes it a perfect candidate for inclusion in these ...CX interface supplied with all the Cartesian produ...ore. Hummingbirds ability to copy plates in secon...
Exhaust Fume Hood from Terra Universal, Inc.
...bel IT siRNA Tracker Intracellular Localization Ki... label and deliver siRNA, of your design, in an ef...racking experiments. Subcellular localization and ...n be monitored following introduction of the label...
Biology Products: